NCT07813377 Usefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing Surgery for Glial Tumors and of the Risk of Postoperative Thromboembolic Disease (GliTEM)
| NCT ID | NCT07813377 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Condition | Glial Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-05-30 |
| Primary Completion | 2027-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-05-30 with a primary completion date of 2027-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of our study is to investigate the clinical significance of thromboelastometric values in the development of thrombotic events and survival in patients with glial tumors, to reduce thromboembolic complications and optimize oncological treatment.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent Exclusion Criteria: * Patients under 18 years of age. * Emergency surgery. * Patients receiving antiplatelet or anticoagulant treatment. * Patients with known hematologic diseases associated with coagulation abnormalities. Examples include: * Congenital or acquired platelet function disorders. * Congenital deficiency of protein C or protein S. * Deficiency of coagulation factors II, V, VII, X, XII. * Glanzmann thrombasthenia. * Hemophilia A, B, or C. * Idiopathic thrombocytopenic purpura (ITP). * von Willebrand disease (types I, II, and III). * Systemic diseases that cause significant coagulation time alterations: * Prothrombin time \< 60%. * Activated partial thromboplastin time (aPTT) \> 50 seconds. * Patients with suspected glial or neuroglial tumor in the context of long-standing epilepsy
Contact & Investigator
Paola Hurtado Restrepo, MD, PhD
PRINCIPAL INVESTIGATOR
Hospital Clinic of Barcelona
Frequently Asked Questions
Who can join the NCT07813377 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glial Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07813377 currently recruiting?
Yes, NCT07813377 is actively recruiting participants. Contact the research team at phurtado@clinic.cat for enrollment information.
Where is the NCT07813377 trial being conducted?
This trial is being conducted at Barcelona, Spain.
Who is sponsoring the NCT07813377 clinical trial?
NCT07813377 is sponsored by Fundacion Clinic per a la Recerca Biomédica. The principal investigator is Paola Hurtado Restrepo, MD, PhD at Hospital Clinic of Barcelona. The trial plans to enroll 100 participants.